AtriCure First Quarter 2025 Earnings: EPS Beats Expectations

AtriCure (NASDAQ:ATRC) First Quarter 2025 Results

Key Financial Results

• Revenue: US$123.6m (up 14% from 1Q 2024).
• Net loss: US$6.75m (loss narrowed by 49% from 1Q 2024).
• US$0.14 loss per share (improved from US$0.28 loss in 1Q 2024).

We've found 21 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free.

All figures shown in the chart above are for the trailing 12 month (TTM) period

AtriCure EPS Beats Expectations

Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 40%.

Looking ahead, revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 8.0% growth forecast for the Medical Equipment industry in the US.

Performance of the American Medical Equipment industry.

The company's shares are down 11% from a week ago.

Risk Analysis

You still need to take note of risks, for example - AtriCure has 1 warning sign we think you should be aware of.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.